Clinical trials: Endocrine Disorders of Female Reproductive System
Epithelial Ovarian Cancer, Acute Kidney Injury Due to Circulatory Failure
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
Ovarian cancer is the most lethal malignancy of the female genital tract. Cytoreductive surgery combined with chemotherapy is the primary treatment for ovarian cancer, and radical tumor resection is an important means to improve…
- Trial name
- NCT05877911
- Testing
- Sodium Sulfate, Hydration, Cisplatin
- Volunteers
- 110 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hypogonadotropic Hypogonadism, Reproductive Disorder
The Molecular Basis of Inherited Reproductive Disorders
The goal of this study is to learn more about the genes that control puberty and reproduction in humans.
- Conditions
- Hypogonadotropic Hypogonadism, Reproductive Disorder, Kallmann Syndrome, Delayed Puberty
- Trial name
- NCT05971836
- Where
- United States
- Volunteers
- 854 people
- Sponsor
- Stephanie B. Seminara, MD
Ovarian Cancer
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
An experimental treatment with OvaRex® MAb-B43.13 (oregovomab), called immunotherapy is being tested in ovarian cancer patients. Immunotherapy causes the body's defenses to react against cancer cells.
- Trial name
- NCT00086632
- Testing
- oregovomab
- Volunteers
- 40 people
- Sponsor
- Unither Pharmaceuticals
Ovarian Cancer
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells.
- Trial name
- NCT00002568
- Testing
- cisplatin, paclitaxel, conventional surgery
- Where
- 55 sites in United States
- Volunteers
- 470 people
- Sponsor
- Gynecologic Oncology Group
Microbiota, Ovarian Neoplasms
Pelvic Microbiomes of Benign and Malignant Ovarian Diseases
This case-control study aims to compare the pelvic microbiomes of benign ovarian diseases and ovarian malignancies by 16s RNA techniques and culture.
- Conditions
- Microbiota, Ovarian Neoplasms, Ribosome Alteration
- Trial name
- MTBOD-1 (NCT03388996)
- Testing
- microbiomes
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Lei Li
Adenocarcinoma, Ovarian Neoplasms
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
2.0 Study Objectives: 2.1 To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients for first-line treatment.
- Conditions
- Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
- Trial name
- NCT00443196
- Testing
- MiCK Assay
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pierian Biosciences
Prostate Cancer, Breast Cancer
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Background: Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT01441089
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube…
- Conditions
- Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02996825
- Testing
- Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Ovary Cancer
Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors: VALTIVE1
Tumours require a blood supply to provide them with oxygen and nutrients and to enable spread of cancer through blood vessels to other organs (metastasis).
- Trial name
- VALTIVE1 (NCT04523116)
- Where
- 4 sites in United Kingdom
- Volunteers
- 176 people
- Sponsor
- University of Manchester
Cancer
Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation.
- Trial name
- NCT00089141
- Testing
- mycophenolate mofetil
- Where
- 16 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Martin, Paul
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Ovarian Neoplasms
Additive Role of ADC Value to ORADS in Adnexal Lesions
Evaluation of the impact of adding mean apparent diffusion coefficient (ADC mean) measurements to the Ovarian-Adnexal Imaging Reporting and Data System MRI (O-RADS MRI) scoring for adnexal lesion characterization using a combined…
- Trial name
- NCT07202429
- Testing
- MRI
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Cairo University
Ovarian Cancer, Ovarian Carcinoma
A Study of Intra-operative Imaging in Women With Ovarian Cancer
The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard…
- Trial name
- NCT04878094
- Testing
- Intravenous Indocyanine Green/ICG injection, PINPOINT endoscopic fluorescence imaging system, Endoscopy
- Where
- 9 sites in United States
- Volunteers
- 155 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Menstrual Disorder, Premature Ovarian Failure
The Effect of HPV Vaccine on Menstrual Cycle in Women of Reproductive Age
Cervical cancer is one of the most common cancer in women, making it the fourth largest cause of female cancer mortality worldwide.
- Trial name
- NCT05838157
- Testing
- prophylactic HPV vaccine(bivalent HPV、quadrivalent HPV、9-valent HPV)
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Adrenal Hyperplasia, Congenital
Questionnaire Study to Assess the Outcomes of the Management of Congenital Adrenal Hyperplasia Individuals
This is a questionnaire study involving women and young girls affected by Congenital Adrenal Hyperplasia (CAH) and their parents.
- Trial name
- CAH-MaS (NCT05228652)
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust
Ovarian Germ Cell Cancer, Ovarian Neoplasms
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian…
- Conditions
- Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer
- Trial name
- MOGCT-01 (NCT02429687)
- Testing
- Paclitaxel, Carboplatin, Bleomycin
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Beihua Kong
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor
Collecting Tumor Samples From Patients With Gynecological Tumors
This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in…
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
- Trial name
- NCT00897442
- Testing
- Laboratory Biomarker Analysis
- Where
- 187 sites in United States
- Volunteers
- 275 people
- Sponsor
- Gynecologic Oncology Group
Endocrine Disease, Infertility
Hormonal Regulation of Puberty and Fertility
Background: The body produces gonadotropin-releasing hormone (GnRH) about every 2 hours. GnRH travels through the bloodstream to the pituitary gland, where it stimulates the gland to produce hormones called gonadotropins.
- Conditions
- Endocrine Disease, Infertility, Hypogonadism, Amenorrhea
- Trial name
- NCT01511588
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Breast Cancer, Hereditary Breast and Ovarian Cancer
Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
- Trial name
- PROGECT (NCT02302742)
- Where
- 11 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Effects of Chemotherapy
The Longitudinal Ovarian Reserve Study
Postmenarchal female cancer patients scheduled to undergo cancer therapy may enroll in this study to assess changes in existing and novel surrogate measures of fertility potential before, during and after chemotherapy.
- Trial name
- NCT02395341
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania